NewsRoom Articles - Page 117 of 207

MondayFeb 07, 2022 9:30 am

Combination of Two Existing Therapies May Help Treat Pediatric Brain Cancer

Researchers at the Catholic University of the Sacred Heart medical school in Italy and Johns Hopkins Medicine in Boston have found new evidence suggesting that a prospective copper therapy can be used to help save children suffering from medulloblastoma. Medulloblastoma is a rapidly growing central nervous system cancer that originates in the spinal cord or brain. This cancer is the most common pediatric brain malignancy and mainly seen in children aged 10 and below. Figures show that about 500 cases of this particular cancer are diagnosed yearly. The rate of survival for children suffering from medulloblastoma when the disease hasn’t…

FridayFeb 04, 2022 9:30 am

Depression, PTSD and Addiction Levels Continue to Rise as Omicron Cases Increase

Data from the Mental Health Index shows that mental health in America has hit an all-time low as the COVID-19 pandemic rages on. The rates of addiction, depression and post-traumatic stress disorder are soaring, as cases of omicron increase. Currently, one in four workers in America has screened positive for PTSD. This is a 54% increase in the last three months and a 135% increase when compared to the levels recorded prior to the pandemic. Rates of depression have also grown by 86% since fall, which is 63% higher than prepandemic levels. A significant increase in addiction in men has…

ThursdayFeb 03, 2022 10:53 am

Study Suggests That Chemotherapy Administration Time May Impact Effectiveness

A new study has found that chemotherapy that is administered at night can target brain tumors better, as observed in mouse models, in comparison to day-time administered chemotherapy. The researchers hypothesize that the blood-brain barrier may allow the cancer treatment to pass through more easily at night. The blood-brain barrier helps prevent foreign substances such as germs and toxins from accessing the brain. However, it also makes it harder to treat tumors as it blocks chemotherapy from entering the brain. Currently, individuals on chemotherapy usually receive their treatment during the day. The team of researchers carrying out the study is…

ThursdayFeb 03, 2022 10:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market Following New Product Launch, Key Acquisition

Cannabicitran is the first of four new rare cannabinoids InMed is planning to launch in the first half of the year to meet growing inbound demand The launch demonstrates InMed’s ability to produce rare cannabinoids at scale, something only very few companies have achieved BayMedica acquisition, other key achievements in 2021, are positioning the company as a leading supplier of rare cannabinoids in the health and wellness sector A leader in the research, development, manufacturing and commercialization of rare cannabinoids, InMed Pharmaceuticals (NASDAQ: INM) has begun the new year from a more prominent position in the market, following key acquisitions…

WednesdayFeb 02, 2022 12:40 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses

Canadian-based mental health treatment-focused biotechnology company Mydecine Innovations Group has been advancing research on the use and improvement of compounds found in nature, particularly the psychedelic psilocybin compound Mydecine recently announced an LOI with The Newly Institute to use Mydecine’s psilocybin and MDMA for treatment at The Newly’s mental health clinics nationwide The LOI is the first collaboration under Mydecine’s SASSP program, which will provide psychedelic drug products and related services to physicians, clinics and hospitals in Canada for psychotherapy Health Canada announced earlier this month that the government has amended its medicinal regulations to allow psilocybin and MDMA prescriptions…

WednesdayFeb 02, 2022 11:18 am

Lung Cancer Not Just a Smoker’s Problem

February 4 is World Cancer Day, which makes this an ideal time to discuss smoking and lung cancer. Globally, lung cancer is one of the most common causes of cancer death, with estimates from the World Health Organization (“WHO”) showing that roughly 90% of lung cancer cases can be prevented by eliminating the use of tobacco. Individuals who smoke have a high risk of developing this disease, with studies also linking smokeless tobacco to lung cancer. Did you know, however, that lung cancer can also develop in individuals who don’t use tobacco? Dr. Aaron Mansfield, an oncologist who specializes in…

TuesdayFeb 01, 2022 2:27 pm

Study Finds That Boosting T Cells May Improve Survival of Patients with Glioblastoma

New research has found that the combined use of radiation and IL-7 (interleukin 7), which is an immune-boosting protein, improves survival rates for mice with glioblastoma. Glioblastoma is a cancer that occurs in an individual’s spinal cord or brain. The conventional treatment for this fatal cancer is chemotherapy and radiation, with figures showing that only about 10% of patients survive for more than five years after being diagnosed with this aggressive cancer, which is resistant to new immunotherapies. The study was carried out by researchers at the School of Medicine at the Washington University in St. Louis. They found that…

MondayJan 31, 2022 1:05 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year

Upcoming study supports CYBN’s mission to develop psychedelics into therapeutics. Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. Study may provide crucial “mind-imaging” information that has been previously missing. Cybin (NEO: CYBN) (NYSE American: CYBN) is starting off the new year right — the company has received approval from an Institutional Review Board (“IRB”) for a feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow. Enrollment for the study begins early this year (https://ibn.fm/XTXAe). “By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after…

MondayJan 31, 2022 12:45 pm

Microsoft Corp. (NASDAQ: MSFT) Partners with Major Organizations to Promote AI Innovation in Healthcare

Microsoft (NASDAQ: MSFT) has formed an alliance, the Artificial Intelligence Industry Innovation Coalition (“AI3C”), with major health and life science organizations in the United States. The tech giant’s aim is to create and track new artificial intelligence innovations as the use of AI in healthcare grows. These organizations include the University of Virginia, the University of California-San Diego, Providence, Plug and Play, Novant Health, Intermountain Healthcare, Duke Health, Cleveland Clinic and the Brookings Institution. A survey conducted by Optum revealed that a significant number of healthcare executives plan to adopt or have adopted AI strategies. Senior executives from these organizations…

FridayJan 28, 2022 12:44 pm

Study Finds That Patients with Childhood Trauma May Benefit from PTSD Treatment

A new study has found that adults who were mistreated or abused as children and suffer from PTSD as a result of this may benefit from cognitive behavioral therapy. The study was carried out by a team of 15 therapists led by Danielle Oprel, a clinical psychologist, and Chris Hoeber, a PhD candidate and researcher. The researchers are hopeful about the perspective the study’s findings provide to individuals with serious PTSD symptoms. Hoeber’s objective was to determine which form of prolonged exposure therapy was the most effective for this particular group. The study was comprised of 149 patients, most of…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Combination of Two Existing Therapies May Help Treat Pediatric Brain Cancer

Depression, PTSD and Addiction Levels Continue to Rise as Omicron Cases Increase

Study Suggests That Chemotherapy Administration Time May Impact Effectiveness

InMed Pharmaceuticals Inc. (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market Following New Product Launch, Key Acquisition

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses

Lung Cancer Not Just a Smoker’s Problem

Study Finds That Boosting T Cells May Improve Survival of Patients with Glioblastoma

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year

Microsoft Corp. (NASDAQ: MSFT) Partners with Major Organizations to Promote AI Innovation in Healthcare

Study Finds That Patients with Childhood Trauma May Benefit from PTSD Treatment

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search